ArticleGynecologic oncology reports2025
Human epidermal growth factor receptor-2, nectin-4, and trophoblast cell surface antigen-2 expression in endometrial carcinosarcoma.
Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Antibody-drug conjugates in gynaecological cancers: opportunities and challenges.Nature reviews. Clinical oncology · 2026Review
- Sacituzumab Tirumotecan Across Gynecologic Malignancies: One Target, Multiple Diseases.Current oncology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To characterize the immunohistochemical expression of human epidermal growth factor receptor-2 (HER2), nectin-4, and trophoblast cell surface antigen-2 (TROP2) in endometrial carcinosarcoma (ECS), with particular attention to compartment-specific expression patterns and potential therapeutic implications. Methods: We retrospectively analyzed 56 ECS cases and performed immunohistochemistry for HER2, nectin-4, and TROP2 on representative tumor sections. Expression levels were semi-quantitatively scored and compared between the carcinomatous and sarcomatous components. Associations with clinicopathological features were also assessed. Results: HER2 overexpression (3+) was identified in 4 cases (7.1 %), with an additional 6 cases (10.7 %) showing equivocal (2+) staining. HER2 2+/3+ expression was significantly associated with serous carcinoma differentiation (31.0 % vs. 3.7 %, Conclusions: HER2, nectin-4, and TROP2 are preferentially expressed in the carcinomatous component of ECS. HER2-targeted antibody-drug conjugates may be a promising therapeutic strategy for ECS with serous carcinoma differentiation. Further investigation is warranted to determine the clinical relevance of targeting nectin-4 and TROP2 in ECS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.